Evidence map›Paper›PMID 33508189›Full record

ArticleJournal of medicinal chemistry2021

Nonpungent N-AVAM Capsaicin Analogues and Cancer Therapy.

Stephen D Richbart, Jamie R Friedman, Kathleen C Brown, Rama S Gadepalli, Sarah L Miles, John M Rimoldi, Gary O Rankin, Monica A Valentovic, Maria T Tirona, Paul T Finch and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Anticancer Activity of Region B Capsaicin Analogs.Journal of medicinal chemistry · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Stephen D RichbartDepartment of Biomedical Sciences, Toxicology Research Cluster, Joan C. Edwards School of Medicine, Marshall University, 1700 Third Avenue, Huntington, West Virginia 25755, United States.
Jamie R FriedmanBioAgilytix Inc., 2300 Englert Drive, Durham, North Carolina 27713, United States.
Kathleen C BrownDepartment of Biomedical Sciences, Toxicology Research Cluster, Joan C. Edwards School of Medicine, Marshall University, 1700 Third Avenue, Huntington, West Virginia 25755, United States.
Rama S GadepalliDepartment of Biomolecular Sciences, School of Pharmacy, Thad Cochran Research Center, University of Mississippi, University Avenue, University, Mississippi 38677, United States.
Sarah L MilesDepartment of Biomedical Sciences, Toxicology Research Cluster, Joan C. Edwards School of Medicine, Marshall University, 1700 Third Avenue, Huntington, West Virginia 25755, United States.
John M RimoldiDepartment of Biomolecular Sciences, School of Pharmacy, Thad Cochran Research Center, University of Mississippi, University Avenue, University, Mississippi 38677, United States.
Gary O RankinDepartment of Biomedical Sciences, Toxicology Research Cluster, Joan C. Edwards School of Medicine, Marshall University, 1700 Third Avenue, Huntington, West Virginia 25755, United States.
Monica A ValentovicDepartment of Biomedical Sciences, Toxicology Research Cluster, Joan C. Edwards School of Medicine, Marshall University, 1700 Third Avenue, Huntington, West Virginia 25755, United States.
Maria T TironaDepartment of Hematology-Oncology, Edwards Cancer Center, Joan C. Edwards School of Medicine, Marshall University, 1400 Hal Greer Boulevard, Huntington, West Virginia 25755, United States.
Paul T FinchDepartment of Oncology, Edwards Cancer Center, Joan C. Edwards School of Medicine, Marshall University, 1400 Hal Greer Boulevard, Huntington, West Virginia 25755, United States.
Joshua A HessDepartment of Oncology, Edwards Cancer Center, Joan C. Edwards School of Medicine, Marshall University, 1400 Hal Greer Boulevard, Huntington, West Virginia 25755, United States.
Piyali DasguptaDepartment of Biomedical Sciences, Toxicology Research Cluster, Joan C. Edwards School of Medicine, Marshall University, 1700 Third Avenue, Huntington, West Virginia 25755, United States.ORCID 0000-0001-6382-3301
Marshall University · USUniversity of Mississippi · USMycosynthetix (United States) · US

Funding

WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI Travis Salisbury · 2012 to 2026
$61.1M
Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI WILLETT, KRISTINE L · 2018 to 2022
$5.3M
Capsaicin and Small cell Lung Cancer TherapyR15CA161491 · NCI · MARSHALL UNIVERSITY · PI DASGUPTA, PIYALI · 2012 to 2021
$1.3M
NCI NIH HHS R15 CA161491NIGMS NIH HHS P20 GM103434NIGMS NIH HHS P30 GM122733
6 · The paper itself

Abstract

Capsaicin displays robust growth-inhibitory activity in multiple human cancers. However, the feasibility of capsaicin as a clinically relevant anticancer drug is hampered by its adverse side effects. This concern has led to extensive research focused on the isolation and synthesis of second-generation nonpungent capsaicin analogues with potent antineoplastic activity. A major class of nonpungent capsaicin-like compounds belongs to the

Indexed as

AnimalsAntineoplastic Agents, PhytogenicCapsaicinHumansNeoplasmsAntineoplastic Agents, PhytogenicCapsaicin

Identifiers

PMID33508189
PMCPMC10442063
OpenAlexW3124526267

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.